Scheduling, administration, biomarkers, and practical guidance.
Cycle 4-12 weeks, then 4-week washout before resuming
Cycle 8-12 weeks; clinical/orphan dose of 40 mg SQ daily used in Barth Syndrome trials — not for general use
Extended 26-52 week protocols for visceral adipose tissue management
Prolonged MOTS-c use risks AMPK desensitization — strict washout compliance is critical
Aligns with circadian metabolic priming; AMPK activation supports fasted-state glucose partitioning and pre-exercise metabolic readiness
Mitochondrial membrane stabilization benefits from pre-exercise timing to reduce ROS during training; morning dosing on rest days
GH secretion peaks nocturnally; evening dosing may synergize with endogenous pulsatility. Morning is acceptable if evening is impractical
Both activate AMPK — concurrent dosing may cause additive hypoglycemia and excessive pathway stimulation